Why DENTSPLY SIRONA (XRAY) Is Down 12.5% After CFO Departure and Weak Q3 Results – And What's Next

• On October 31, 2025, DENTSPLY SIRONA announced that Chief Financial Officer Matthew E. Garth would step down effective November 5, with CEO Daniel T. Scavilla assuming interim CFO duties while a search for a new executive begins.
• This leadership change was announced alongside third quarter results showing year-over-year declines in sales and ongoing net losses, highlighting continued operational and financial challenges for the company.
• We'll explore how the CFO transition amid ongoing losses may influence DENTSPLY SIRONA's investment narrative and outlook.

These 12 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

DENTSPLY SIRONA Investment Narrative Recap

To be a shareholder in DENTSPLY SIRONA, you need to believe in the company's ability to restore growth by capitalizing on digital dentistry adoption and operational improvements, despite recent sales declines and net losses. The abrupt CFO transition, set against ongoing profitability challenges, could further intensify short-term uncertainty around execution, a critical factor for the company’s streamlining efforts and cost controls. While this management change is significant, its immediate impact on near-term catalysts and risks appears limited unless it disrupts ongoing turnaround initiatives.

The timing of the CFO departure coincides with the latest earnings announcement, which highlighted another year-over-year drop in quarterly sales along with a substantial net loss. These results reinforce the central risk for DENTSPLY SIRONA: persistent weakness in revenue growth and margin pressure, particularly in key markets, may continue to overshadow other operational goals. But in contrast to the management shakeup, investors should be aware of...

Read the full narrative on DENTSPLY SIRONA (it's free!)

DENTSPLY SIRONA is forecast to achieve $3.9 billion in revenue and $502.2 million in earnings by 2028. This outlook assumes annual revenue growth of 2.3% and reflects an increase in earnings of about $1.45 billion from current earnings of -$949.0 million.

Uncover how DENTSPLY SIRONA's forecasts yield a $16.00 fair value, a 45% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members submitted three fair value estimates for DENTSPLY SIRONA, ranging widely from US$16.00 to US$34.81 per share. Against this backdrop, the persistent revenue slowdown and margin compression risk highlighted in recent results could frame your perspective on where the business goes next, consider reviewing these varied viewpoints before you decide.

Explore 3 other fair value estimates on DENTSPLY SIRONA - why the stock might be worth just $16.00!

Build Your Own DENTSPLY SIRONA Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your DENTSPLY SIRONA research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free DENTSPLY SIRONA research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate DENTSPLY SIRONA's overall financial health at a glance.

Interested In Other Possibilities?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• We've found 17 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com